Journals / Journal of Clinical and Analytical Medicine / 2016 / Cilt: 7 - Sayı: 4

Vernal Keratokonjonktivit TedavisindeTopikal Olopatadin ve Siklosporin Kullanımı

Topical Use of Olopatadine and Cyclosporine ain Treatment of Vernal Keratoconjunctivitis

Pages
488–493
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In terms of improvement regarding the objective signs, Cyclosporine A was seen to be more effective in the late period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To compare the efficacy and safety of Olopatadine hydrochloride (0.1%) with Cyclosporine A ophthalmic solution (0.05%) in treating the signs and symptoms of VKC.
📊
Key Findings & Data:Results: There was no significant difference between the Olopatadine group and the Cyclosporine A group regarding subjective symptoms at the 3rd, 6th, 12th, and 18th month.
💡
Conclusion & Impact:In terms of improvement regarding the objective signs, Cyclosporine A was seen to be more effective in the late period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To compare the efficacy and safety of Olopatadine hydrochloride (0.1%) with Cyclosporine A ophthalmic solution (0.05%) in treating the signs and symptoms of VKC. Material and Method: Twenty-five patients with VKC were included in a prospective study. One eye of each patient was treated with Olopatadine while the other eye was treated with Cyclosporine A. Subjective symptoms of the patients such as itching, tearing, foreign body sensation, and mucus discharge were recorded and scored. The objective signs, such as the presence of giant papillae on the tarsal conjunctiva, bulbar conjunctival hyperemia, keratitis, limbal hypertrophy, corneal vascularization, and conjunctival cicatrization, were scored. Results: There was no significant difference between the Olopatadine group and the Cyclosporine A group regarding subjective symptoms at the 3rd, 6th, 12th, and 18th month. There was a significant improvement in the subjective symptoms of both groups. No significant difference was seen between the groups with regard to objective signs. A significant improvement was observed in the Cyclosporine group in the late period of the study. Discussion: In long-term therapy of VKC, similar effects were seen regarding improvement in the subjective symptoms during the use of topical Olopatadine and Cyclosporine A. In terms of improvement regarding the objective signs, Cyclosporine A was seen to be more effective in the late period.

Özet

Amaç: Vernal Keratokonjonktivit (VKK) tedavisinde Olopatadin hidroklorid (0.1%) ile Siklosporin A (0.05%) göz solüsyonun (0.05%) etki ve güvenirliğini değerlendirmektir. Gereç ve Yöntem: VKK olan 25 hasta prospektif olarak değerlendirildi. Her hastanın bir gözüne Olopatadin hidroklorid (0.1%), diğer gözüne Siklosporin A (0.05%) damlatıldı. Kaşıntı, sulanma, yabancı cisim hissi ve mucus sekresyon gibi subjektif semptomların varlığı kaydedildi ve skorlandı. Tarsal konjonktivada dev papilla varlığı, bulber konjonktiva hiperemisi, keratit, limbal hipertrofi, korneal vaskularizasyon ve konjonktival skar oluşumu gibi objektif belirtiler kaydedildi ve skorlandı. Bulgular: Olopatadin ve Siklosporin gruplarında subjektif semptomlarda anlamlı bir düzelme görüldü. İki grup arasında subjektif semptomlar açısından arasında 3., 6., 12. ve 18. ayda anlamlı fark görülmedi. Gruplar arasında objektif bulgular açısından anlamlı fark izlenmedi. Geç dönemde Siklosporin grubunda anlamlı bir iyileşme görüldü. Tartışma: VKK uzun dönem tedavisinde Olopatadin ve Siklosporin A kullanımı ile subjektif semptomlarda benzer etkiler görüldü. Objektif bulguların iyileşmesinde ise geç dönemde Siklosporin A'nın daha etkili olduğu izlendi.

🔖

Cite This Article

KANTARCI, F. A., ZAURE, K., FİKRET, A., EUGENİU, V. (2022). Vernal Keratokonjonktivit TedavisindeTopikal Olopatadin ve Siklosporin Kullanımı. Journal of Clinical and Analytical Medicine, Cilt: 7 - Sayı: 4, 488–493. https://ajindex.com/articles/652336

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol;87(2):133-47.
  2. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol 2013;97(1):9-14.
  3. Jun J, Bielory L, Raizman MB. Vernal conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):59-82.
  4. Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treat- ment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep 2013;13(3):308-14. Chigbu DI. The management of allergic eye diseases in primary eye care. Cont Lens Anterior Eye 2009; 32(6):260-72.
  5. Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P. A double-masked comparison of 0.1% tacrolimus oint- ment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivi- tis in children. Asian Pac J Allergy Immunol 2012; 30(3):177-84.
  6. Pacharn P, Vichyanond P. Immunomodulators for conjunctivitis. Curr Opin Allergy Clin Immunol 2013;13(5):550-7.
  7. Kumar S, Gupta N, Vivian AJ. Modern approach to managing vernal keratocon- junctivitis. Curr Allergy Asthma Rep 2010;10(3):155-62.
  8. Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother 2010;11(6):969-81.
  9. Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical cyclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol;90(4):461-4.
  10. McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol 2012;6:1731-8. Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin Ophthalmol 2008;2(3):525-31.
  11. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first oph- thalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol.; 4(4):453-61.
  12. Corum I, Yeniad B, Bilgin LK, Ilhan R. Efficiency of olopatadine hydrochloride 1% in the treatment of vernal keratoconjunctivitis and goblet cell density. J Ocul Pharmacol Ther 2005;21(5):400-5.
  13. Wan KH, Chen LJ, Rong SS, Pang CP, Young AL. Topical Cyclosporine in the Treatment of Allergic Conjunctivitis: A Meta-analysis. Ophthalmology;120(11):2197-203.
  14. Oray M, Toker E. Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05% cyclosporine a therapy. Cornea. 2013;32(8):1149-54.
  15. Kosrirukvongs P, Luengchaichawange C. Topical cyclosporine 0.5 p